They have more than enough to run the Tox studies and still have plenty left, but no doubt before going into trials they will need to raise or find someone with deep pockets/jv/licence deal
If they were to raise, knowing the likely success of the Tox studies with previous resilts will be positive they would be folly to raise at lows....
In the mean time $50-$100-$150k perday shaking is filling someones positions and with these numbers it is only retail investers that are letting go....
4.8c this time last year with NO engineering run, NO grants from Perth, No added grant from Oliver Newton John's charity, PX-3 still in the bottom draw and many many more things since then and we are yearly lows....
Delays, market sentiment as a whole, interest rates and so on have had a major effect, but in with all that PAB has only strenghtened what it has and will have its day in the sun again soon....
Cheap imho is an understatement..
Short term future of PAB, page-69
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
